BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26650627)

  • 1. Malignant pheochromocytomas/paragangliomas harbor mutations in transport and cell adhesion genes.
    Wilzén A; Rehammar A; Muth A; Nilsson O; Tešan Tomić T; Wängberg B; Kristiansson E; Abel F
    Int J Cancer; 2016 May; 138(9):2201-11. PubMed ID: 26650627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing.
    Crona J; Delgado Verdugo A; Maharjan R; Stålberg P; Granberg D; Hellman P; Björklund P
    J Clin Endocrinol Metab; 2013 Jul; 98(7):E1266-71. PubMed ID: 23640968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.
    Castro-Vega LJ; Buffet A; De Cubas AA; Cascón A; Menara M; Khalifa E; Amar L; Azriel S; Bourdeau I; Chabre O; Currás-Freixes M; Franco-Vidal V; Guillaud-Bataille M; Simian C; Morin A; Letón R; Gómez-Graña A; Pollard PJ; Rustin P; Robledo M; Favier J; Gimenez-Roqueplo AP
    Hum Mol Genet; 2014 May; 23(9):2440-6. PubMed ID: 24334767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
    Korpershoek E; Petri BJ; van Nederveen FH; Dinjens WN; Verhofstad AA; de Herder WW; Schmid S; Perren A; Komminoth P; de Krijger RR
    Endocr Relat Cancer; 2007 Jun; 14(2):453-62. PubMed ID: 17639058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
    Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
    Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression.
    Tomić TT; Olausson J; Rehammar A; Deland L; Muth A; Ejeskär K; Nilsson S; Kristiansson E; Wassén ON; Abel F
    PLoS Genet; 2020 Jun; 16(6):e1008803. PubMed ID: 32511227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATRX driver mutation in a composite malignant pheochromocytoma.
    Comino-Méndez I; Tejera ÁM; Currás-Freixes M; Remacha L; Gonzalvo P; Tonda R; Letón R; Blasco MA; Robledo M; Cascón A
    Cancer Genet; 2016 Jun; 209(6):272-7. PubMed ID: 27209355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genomic landscape of phaeochromocytoma.
    Flynn A; Benn D; Clifton-Bligh R; Robinson B; Trainer AH; James P; Hogg A; Waldeck K; George J; Li J; Fox SB; Gill AJ; McArthur G; Hicks RJ; Tothill RW
    J Pathol; 2015 May; 236(1):78-89. PubMed ID: 25545346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas.
    McInerney-Leo AM; Marshall MS; Gardiner B; Benn DE; McFarlane J; Robinson BG; Brown MA; Leo PJ; Clifton-Bligh RJ; Duncan EL
    Clin Endocrinol (Oxf); 2014 Jan; 80(1):25-33. PubMed ID: 24102379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking pheochromocytomas and paragangliomas from a genomic perspective.
    Castro-Vega LJ; Lepoutre-Lussey C; Gimenez-Roqueplo AP; Favier J
    Oncogene; 2016 Mar; 35(9):1080-9. PubMed ID: 26028031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series.
    Oudijk L; de Krijger RR; Rapa I; Beuschlein F; de Cubas AA; Dei Tos AP; Dinjens WN; Korpershoek E; Mancikova V; Mannelli M; Papotti M; Vatrano S; Robledo M; Volante M
    J Clin Endocrinol Metab; 2014 Jul; 99(7):E1376-80. PubMed ID: 24684458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.
    Neumann HP; Pawlu C; Peczkowska M; Bausch B; McWhinney SR; Muresan M; Buchta M; Franke G; Klisch J; Bley TA; Hoegerle S; Boedeker CC; Opocher G; Schipper J; Januszewicz A; Eng C;
    JAMA; 2004 Aug; 292(8):943-51. PubMed ID: 15328326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
    Klein RD; Jin L; Rumilla K; Young WF; Lloyd RV
    Diagn Mol Pathol; 2008 Jun; 17(2):94-100. PubMed ID: 18382370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.
    Burnichon N; Cascón A; Schiavi F; Morales NP; Comino-Méndez I; Abermil N; Inglada-Pérez L; de Cubas AA; Amar L; Barontini M; de Quirós SB; Bertherat J; Bignon YJ; Blok MJ; Bobisse S; Borrego S; Castellano M; Chanson P; Chiara MD; Corssmit EP; Giacchè M; de Krijger RR; Ercolino T; Girerd X; Gómez-García EB; Gómez-Graña A; Guilhem I; Hes FJ; Honrado E; Korpershoek E; Lenders JW; Letón R; Mensenkamp AR; Merlo A; Mori L; Murat A; Pierre P; Plouin PF; Prodanov T; Quesada-Charneco M; Qin N; Rapizzi E; Raymond V; Reisch N; Roncador G; Ruiz-Ferrer M; Schillo F; Stegmann AP; Suarez C; Taschin E; Timmers HJ; Tops CM; Urioste M; Beuschlein F; Pacak K; Mannelli M; Dahia PL; Opocher G; Eisenhofer G; Gimenez-Roqueplo AP; Robledo M
    Clin Cancer Res; 2012 May; 18(10):2828-37. PubMed ID: 22452945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HRAS mutation prevalence and associated expression patterns in pheochromocytoma.
    Stenman A; Welander J; Gustavsson I; Brunaud L; Bäckdahl M; Söderkvist P; Gimm O; Juhlin CC; Larsson C
    Genes Chromosomes Cancer; 2016 May; 55(5):452-9. PubMed ID: 26773571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Succinate dehydrogenase B (SDHB) immunohistochemistry in guiding mutational screening among patients with pheochromocytoma-paraganglioma syndromes.
    Pai R; Manipadam MT; Singh P; Ebenazer A; Samuel P; Rajaratnam S
    APMIS; 2014 Nov; 122(11):1130-5. PubMed ID: 24735130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations seen among patients with pheochromocytoma and paraganglioma at a referral center from India.
    Pai R; Ebenazer A; Paul MJ; Thomas N; Nair A; Seshadri MS; Oommen R; Shanthly N; Devasia A; Rebekah G; Jeyaseelan L; Rajaratnam S
    Horm Metab Res; 2015 Feb; 47(2):133-7. PubMed ID: 24977658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.
    Amorim-Pires D; Peixoto J; Lima J
    Cytogenet Genome Res; 2016; 150(3-4):227-241. PubMed ID: 28231563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.